Characterization of Biotherapeutic Beasts by Mass Spectrometry

Published on: 


Thursday, September 29, 2022 at 7am PT | 10am ET | 4pm CET Novel methods have been developed and applied on Biotherapeutics Beasts in the half Megadalton to 3-4 MDa range to measure AAV Full:Empty genome ratio using charge detection mass spectrometry on the Q Exactive UHMR mass spectrometer with Direct Mass Technology mode.

Register Free

Event Overview:

The market of biologics in Biopharma companies is in constant evolution and moved away in the last few years from classical monoclonal antibody to proteins that are more difficult to analyze, such as therapeutics proteins, Antibody drug/molecule conjugates and even in the cell and gene therapy space with Adeno Associated Viruses for example. With all these new modalities, state of the art analytics must be developed to characterize them in details and mass spectrometry is a major player in this arena. Native MS applied to heterogeneous biotherapeutics like ADC and other complex format is heavily used. More recently Charge Detection Mass Spectrometry (CD-MS) has become commercially available as Thermo Scientific™ Direct Mass Technology™ mode on the Thermo Scientific™ Q Exactive™ UHMR mass spectrometer. Methods have been developed and applied on Biotherapeutics Beasts in the half Megadalton to 3-4 MDa range to measure AAV Full:Empty genome ratio.

Key Learning Objectives:

  • Apply mass spectrometry to study biotherapeutics
  • Understand how charge detection mass spectrometry enables native characterization of complex biotherapeutics
  • Learn methods to characterize AAVs, including Full:Empty ratio

Who Should Attend:

  • Laboratory managers
  • Scientists
  • New product developers


Thierry Besson
Senior Scientist II
Novartis Institutes for Biomedical Research

Theirry Besson obtained his master’s degree in analytical chemistry at the University of Rennes – France in 2005. He always used mass spectrometry in the different laboratories he joined, starting at Servier for the structure elucidation of small molecules, then in a fundamental lab research facility in Paris to perform infrared spectroscopy in gas phase. Besson joined Novartis Institutes for Biomedical Research, in 2008, in Patrick Schindler’s lab in the Novartis Biologics Center (NBC), where he started to do characterization of biomolecules by mass spectrometry. First on classical antibodies and then followed by all other kinds of difficult formats to analyze such as bispecific, fusion-protein, therapeutic proteins, ADC, and more recently with Adeno Associated Viruses, Radio Ligand Therapy and oligonucleotides mAb conjugates.

Register Free